Comparison study of liposomal amphotericin B and micafungin in treatment of deep candidasis in surgical and emergency domains
- Conditions
- Invasive Candidiasis
- Registration Number
- JPRN-UMIN000006106
- Lead Sponsor
- Department of Infection Control and Prevention, Aichi Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
(1) Cases treated with L-AMB or MCFG of those enrolled in this study. (2) Patients with a history of hypersensitivity to the ingredients of this product, such as shock (3) Children (younger than 16 years old) (4) Patients undergoing treatment (leukocyte transfusion) that is contraindicated for use in combination with L-AMB. (5)Pregnant or lactating patients or possibly pregnant patients. (6)Patients with a present illness of serious liver diseases not caused by infections or a past history of them. (7) Patients with neutrophil counts of <500 cells/mm3. (8)Patients with serious underlying diseases or infections who are not expected to live throughout the study period. (9) Other patients judged to be unsuitable as subjects by the physicians in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical effect (efficacy ratio) at the end or discontinuation of administration Clinical symptoms between 4 and 7 days after the start of administration Clinical symptoms between 5 and 10 days after the end of administration
- Secondary Outcome Measures
Name Time Method Mycological effect Serological effect